June 24, 2025 04:01 AM GMT M Idea From the Global Director of Research | North America Charts That Caught My Eye A guiding principle at Morgan Stanley Research is to enhance your investment process by delivering unique insights that separate the signal from the noise. An intuitively designed and well-crafted chart can often accomplish this with exceptional clarity. With that mission in mind, these charts in our recently published research stood out to me. Please reach out to me with feedback on these or any ...

Welcome back to Velio on MSNBC. I'm Charles Coleman Jr. . filling in for Ally today.Now, since returning to office, Donald Trump has dismantled decades old agencies and initiatives which were initially designed to protect black Americans and other marginalized communities. He has justified these actions by claiming he's rooting out racial discrimination disguised as diversity, equity, and inclusion. But as Pulitzer Prizewinning journalist Nicole Hannah Jones points out in a new york a new essay for the New ...

Moretus Research delivers state-of-the-art, buy-side quality equity research for serious investors seeking clarity, conviction, and alpha. Focused on U.S. public markets, Moretus applies a structured, repeatable framework to identify companies with durable business models, mispriced cash flow potential, and intelligent capital allocation. Built on institutional standards, Moretus Research combines rigorous fundamental analysis with a high-signal, judgment-driven process—eschewing noise, narrative, and overl ...

Core Insights - Arcutis Biotherapeutics has received FDA approval for its product ZORYVE, a PDE4 inhibitor, which expands the drug's existing label [1] - The company focuses on small and microcap biopharmaceuticals, where mispricing is most intense and institutional attention is limited [1] - The analyst team consists mainly of high-ranking Life Sciences students from top UK universities, aiming to improve the accuracy of clinical stage equity research [1] Company Overview - ZORYVE is positioned favorably among physicians due to its mechanism of action as a PDE4 inhibitor [1] - The company targets young, often clinical stage biopharmaceutical firms that typically lack institutional coverage [1] Market Dynamics - Retail investors make up the majority of public ownership in these small biopharmaceutical companies, leading to price movements that may not reflect material information [1] - Analyst coverage from investment banks often results in significant market movements, despite potential conflicts of interest [1]

Key Takeaways Goldman Sachs stock surged 57.3% over 12 months, outpacing JPMorgan and Morgan Stanley. GS reported IB revenue decline in Q1 2025 but holds a strong M&A backlog and leads in advisory market share. The Fed's capital relief proposal may boost GS' ROE and fund growth in IB, trading and AWM segments.The Goldman Sachs Group, Inc. (GS) shares have surged 57.3% over the past year, outperforming the industry's 40.9% growth. Its peers, JPMorgan (JPM) and Morgan Stanley (MS) , shares rose 48.4% and 50 ...

Group 1 - The investment thesis for Super Micro Computer (SMCI) is characterized as a Hold case, with a long-term fundamental buy bias and valuation concerns noted [1] - The company is considered suitable for aggressive and risk-tolerant investors due to the high risks involved [1] - The analyst emphasizes a focus on equity valuation, market trends, and portfolio optimization to identify high-growth investment opportunities [1] Group 2 - The analyst has over 20 years of experience in quantitative research, financial modeling, and risk management, indicating a strong background in the field [1] - There is a particular interest in macroeconomic trends, corporate earnings, and financial statement analysis, which aims to provide actionable ideas for investors [1]

Private equity tokenization platfrom Jarsy launches out of stealth with pre-seed backing from Breyer Capital https://t.co/dVhPCwGEBF ...

S&P did in fact want to go.New all time on high equity markets.Easy (@EasyEatsBodega):The S&P is 1% off its all time high.I want to think we have a pullback but my god, the tradfi market just seems like it wants to goooooo. ...

Granger for the ones who get it done. >> Welcome back. A big change could be coming to your 401 K after a push from Washington to Wall Street to bring private assets to the masses.Our Leslie Picker has the story for us. Morning, Leslie. >> Hey, good morning Sarah.Obviously, this is very much in focus in the alternative asset world. Blackrock just this morning making a push out with a paper describing their plans for putting more private assets into 401 S. The firm intends to offer a target date fund with as ...

Dora Puhakka was a Speaker at TEDxEspoo Youth 2025! What does it truly mean to connect with another human being? In this TEDx Talk, Dora Puhakka invites us to reflect on one of the most universal human needs: to be seen, to be heard, and to feel that we belong. From the beginning of the Talk we are reminded that human connection is not a luxury - it is a necessity. Yet despite living in an increasingly interconnected world, many of us feel isolated, divided, and misunderstood. This Talk explores how concept ...